5 0 1 0 1 B-treatment
- 1 2 1 2 I-treatment
alpha 2 7 2 7 I-treatment
reductase 8 17 8 17 I-treatment
inhibitors 18 28 18 28 I-treatment
( 29 30 29 30 O
e.g. 30 34 30 34 O
, 34 35 34 35 O
finasteride 36 47 36 47 B-treatment
or 48 50 48 50 O
dutasteride 51 62 51 62 B-treatment
) 62 63 62 63 O

Clinical 0 8 64 72 B-clinical_variable
stage 9 14 73 78 I-clinical_variable
T1a 15 18 79 82 B-lower_bound
- 18 19 82 83 O
T3 19 21 83 85 B-upper_bound
, 21 22 85 86 O
N0 23 25 87 89 O
- 25 26 89 90 O
Nx 26 28 90 92 O
, 28 29 92 93 O
M0 30 32 94 96 O
- 32 33 96 97 O
Mx 33 35 97 99 O

HIGH 0 4 100 104 O
RISK 5 9 105 109 O
: 9 10 109 110 O
CS 11 13 111 113 B-clinical_variable
T2c 14 17 114 117 B-lower_bound
- 17 18 117 118 O
T3 18 20 118 120 B-upper_bound
, 20 21 120 121 O
any 22 25 122 125 O
Gleason 26 33 126 133 B-clinical_variable
, 33 34 133 134 O
any 35 38 135 138 O
PSA 39 42 139 142 B-clinical_variable
, 42 43 142 143 O
or 44 46 144 146 O
CS 47 49 147 149 O
T1 50 52 150 152 B-lower_bound
- 52 53 152 153 O
3 53 54 153 154 O
, 54 55 154 155 O
Gleason 56 63 156 163 O
≥8 64 66 164 166 O
and/or 67 73 167 173 O
PSA≥20 74 80 174 180 O

High 0 4 181 185 O
risk 5 9 186 190 O
group 10 15 191 196 O
: 15 16 196 197 O
three 17 22 198 203 B-treatment
hormone 23 30 204 211 I-treatment
therapy 31 38 212 219 I-treatment
regimens 39 47 220 228 I-treatment

Histologically 0 14 229 243 O
proven 15 21 244 250 O
prostate 22 30 251 259 B-cancer
adenocarcinoma 31 45 260 274 I-cancer

Hormone 0 7 275 282 B-treatment
therapy 8 15 283 290 I-treatment
: 15 16 290 291 O
includes 17 25 292 300 O
LHRH 26 30 301 305 B-treatment
agonists 31 39 306 314 I-treatment
( 40 41 315 316 O
e.g. 41 45 316 320 O
leuprolide 46 56 321 331 B-treatment
, 56 57 331 332 O
goserelin 58 67 333 342 B-treatment
, 67 68 342 343 O
triptorelin 69 80 344 355 B-treatment
) 80 81 355 356 O
, 81 82 356 357 O
antagonists 83 94 358 369 B-treatment
( 95 96 370 371 O
e.g. 96 100 371 375 O
degarelix 101 110 376 385 B-treatment
) 110 111 385 386 O
, 111 112 386 387 O
peripheral 113 123 388 398 B-treatment
blockers 124 132 399 407 I-treatment
( 133 134 408 409 O
e.g. 134 138 409 413 O
flutamide 139 148 414 423 B-treatment
, 148 149 423 424 O
bicalutamide 150 162 425 437 B-treatment
, 162 163 437 438 O
nilutamide 164 174 439 449 B-treatment
) 174 175 449 450 O
, 175 176 450 451 O
estrogens 177 186 452 461 B-treatment
( 187 188 462 463 O
e.g. 188 192 463 467 O
DES 193 196 468 471 B-treatment
) 196 197 471 472 O
and 198 201 473 476 O
bilateral 202 211 477 486 B-treatment
orchiectomy 212 223 487 498 I-treatment

INTERMEDIATE 0 12 499 511 O
RISK 13 17 512 516 O
: 17 18 516 517 O
CS 19 21 518 520 O
T2b 22 25 521 524 B-upper_bound
, 25 26 524 525 O
Gleason 27 34 526 533 B-clinical_variable
≤7 35 37 534 536 O
, 37 38 536 537 O
PSA<20 39 45 538 544 B-clinical_variable
, 45 46 544 545 O
Nx-0 47 51 546 550 O
, 51 52 550 551 O
Mx-0 53 57 552 556 O
, 57 58 556 557 O
or 59 61 558 560 O
CS 62 64 561 563 O
T1a 65 68 564 567 B-lower_bound
- 68 69 567 568 O
T2b 69 72 568 571 O
, 72 73 571 572 O
Gleason 74 81 573 580 O
2 82 83 581 582 O
- 83 84 582 583 O
6 84 85 583 584 B-upper_bound
, 85 86 584 585 O
PSA≥10 87 93 586 592 O
& 94 95 593 594 O
< 96 97 595 596 O
20 97 99 596 598 O
, 99 100 598 599 O
Nx-0 101 105 600 604 O
, 105 106 604 605 O
Mx-0 107 111 606 610 O
, 111 112 610 611 O
or 113 115 612 614 O
CS 116 118 615 617 O
T1a 119 122 618 621 O
- 122 123 621 622 O
T2b 123 126 622 625 O
, 126 127 625 626 O
Gleason 128 135 627 634 O
7 136 137 635 636 O
, 137 138 636 637 O
PSA≤20 139 145 638 644 O
, 145 146 644 645 O
Nx-0 147 151 646 650 O
, 151 152 650 651 O
Mx-0 153 157 652 656 O

Karnofsky 0 9 657 666 B-clinical_variable
performance 10 21 667 678 I-clinical_variable
status 22 28 679 685 I-clinical_variable
70 29 31 686 688 B-lower_bound
- 31 32 688 689 O
100 32 35 689 692 B-upper_bound

Low 0 3 693 696 O
and 4 7 697 700 O
Intermediate 8 20 701 713 O
risk 21 25 714 718 O
groups 26 32 719 725 O
: 32 33 725 726 O
no 34 36 727 729 O
hormone 37 44 730 737 B-treatment
ablation 45 53 738 746 I-treatment
for 54 57 747 750 O
two 58 61 751 754 B-upper_bound
months 62 68 755 761 I-upper_bound
prior 69 74 762 767 I-upper_bound
to 75 77 768 770 O
enrollment 78 88 771 781 O
, 88 89 781 782 O
or 90 92 783 785 O
during 93 99 786 792 O
treatment 100 109 793 802 O

OW 0 2 803 805 O
RISK 3 7 806 810 O
: 7 8 810 811 O
CS 9 11 812 814 O
T1a 12 15 815 818 O
- 15 16 818 819 O
T2a 16 19 819 822 O
, 19 20 822 823 O
Gleason 21 28 824 831 B-clinical_variable
2 29 30 832 833 O
- 30 31 833 834 O
6 31 32 834 835 B-upper_bound
, 32 33 835 836 O
PSA<10 34 40 837 843 B-clinical_variable
, 40 41 843 844 O
Nx-0 42 46 845 849 O
, 46 47 849 850 O
Mx-0 48 52 851 855 O

Prior 0 5 856 861 O
high 6 10 862 866 O
- 10 11 866 867 O
dose 11 15 867 871 O
radiotherapy 16 28 872 884 B-treatment
to 29 31 885 887 O
the 32 35 888 891 O
prostate 36 44 892 900 O
or 45 47 901 903 O
lower 48 53 904 909 O
pelvis 54 60 910 916 O

Prior 0 5 917 922 B-treatment
prostatectomy 6 19 923 936 I-treatment
or 20 22 937 939 O
cryotherapy 23 34 940 951 B-treatment
of 35 37 952 954 I-treatment
the 38 41 955 958 I-treatment
prostate 42 50 959 967 I-treatment

